-
Mashup Score: 1Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value? - 11 month(s) ago
Hospitals in England experience extremely high levels of bed occupancy in the winter. In these circumstances, vaccine-preventable hospitalisations due to seasonal respiratory infections have a high cost because of the missed opportunity to treat other patients on the waiting list. This paper estimates the number of hospitalisations that current vaccines against influenza, pneumococcal disease…
Source: MDPICategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D
-
-
Mashup Score: 1Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
In the April Issue: Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/eVRPb5m04B
-
-
Mashup Score: 2Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D #SGLT2 inhibitors https://t.co/zvuebfno2G
-
-
Mashup Score: 0Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D
-
-
Mashup Score: 3Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOaT5p #T2D
-
-
Mashup Score: 6Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
In the Current Issue: Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D
-
-
Mashup Score: 0Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
In the April Issue: Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D #SGLT2 inhibitors
-
-
Mashup Score: 7The Lancet Diabetes & Endocrinology, April 2023, Volume 11, Issue 4, Pages 217-298, e6 - 1 year(s) ago
Explore the current issue of The Lancet Diabetes & Endocrinology, a monthly journal focussed on diabetes, endocrinology, and metabolism
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
The April Issue of @TheLancetEndo is now online, featuring #ageing, #antiageing, #metformin, growth hormone, #dietary restriction, #obesity, #SGLT2 inhibitors and #hospitalisations, type 2 #diabetes, #menopause, #COVID19, T1D, #hyperthyroidism, & more https://t.co/ft8CFDeSQz https://t.co/odW8ai59hZ
-
-
Mashup Score: 1Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOaT5p #T2D
-
#Vaccine -Preventable #Hospitalisations from #Seasonal #Respiratory #Diseases: What Is Their True Value? https://t.co/MJ3kEmUYly https://t.co/WNdVPpappJ